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UNH Researchers Discover New Inhibitor Drug
Combination for Rare Form of Cancer
Thursday, January 14, 2021
DURHAM, N.H.— Waldenström macroglobulinemia (WM), a rare form of lymphoma, does not have any
known cure and only one FDA-approved treatment making it challenging to treat patients. Researchers
at the University of New Hampshire took the novel approach of targeting specific cell proteins that
control DNA information using inhibitors, or drugs, that were e ective in reducing the growth of the
cancer cells and when combined with a third drug were even more successful in killing the WM cancer
cells which could lead to more treatment options.
“This is the first study to report the promising results of inhibitors in Waldenström macroglobulinemia
which could open the door to new clinical possibilities,” said Sherine Elsawa, associate professor of
molecular, cellular and biomedical sciences. “We know that targeting these types of proteins with
inhibitors can increase high therapeutic results in many other kinds of cancer but desired results in WM cells has been lacking.”
In their study (https://www.futuremedicine.com/doi/10.2217/epi-2020-0189), just published in the journal Epigenomics, Elsawa and her team focused on the
epigenetic regulation of WM cancer cells. Epigenetics is the study of how DNA is opened and closed to allow certain genes to be expressed or encoded. Each protein
has a di erent function—some write the genetic code, some read or interpret it and others can erase the code. The researchers focused on two proteins,
bromodomain and extraterminal (BET), which are epigenetic readers. BET proteins have been shown to be involved in pathological conditions including cancer.
Drugs that inhibit these proteins can block gene expression that regulate cancer cells by slowing and stopping their growth.
The WM cancer cells were treated with the BET inhibitors JQ-1 and I-BET-762 which reduced the growth of the WM cells in the lab. While the dose dependent e ect
was significant for both drugs, JQ-1 showed the strongest inhibitory e ect with 70% reduction in cell proliferation at the highest dose. However, neither inhibitor
was e ective in inducing cell death.
Researchers tried adding three di erent drugs, venetoclax, panabinostat and ibrutinib (the only FDA approved therapy specifically for WM patients), one at a time
in combination with the BET inhibitors ((JQ-1 and I-BET-762). A er studying each separate drug combination, they found that adding venetoclax or panabinostat to
the inhibitors was more e ective than adding ibrutinib—with panobinostat o ering the greatest combination therapy. Although ibrutinib alone has shown e icacy
in WM patients, the study suggests epigenetic targeting is likely to provide a better therapeutic outcome and WM patients undergoing ibrutinib therapy may benefit
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The research was supported by a grant from the International Waldenström Macroglobulinemia Foundation and the Leukemia & Lymphoma Society (IWMF-LLS),
an award from the National Institutes of Health Centers of Biomedical Research Excellence (COBRE) (CIBBR, P20GM113131), and an Institutional Development
Award (IDeA) from the National Institute of General Medical Sciences.
The University of New Hampshire (http://unh.edu) inspires innovation and transforms lives in our state, nation, and world. More than 16,000 students from all 50
states and 71 countries engage with an award-winning faculty in top-ranked programs in business, engineering, law, health and human services, liberal arts and
the sciences across more than 200 programs of study. As one of the nation’s highest-performing research universities, UNH partners with NASA, NOAA, NSF and
NIH, and receives more than $110 million in competitive external funding every year to further explore and define the frontiers of land, sea and space.
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